A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.

Trial Details

NCT ID
NCT06434610
Phase
PHASE2
Sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • B013
  • Paclitaxel
  • Placebo
Locations (sample)
  • Beijing, China|39.9075,116.39723
  • Bengbu, China|32.94083,117.36083
  • Changsha, China|28.19874,112.97087
  • Fuzhou, China|26.06139,119.30611
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Subjects who voluntarily participate in this study and sign informed consent form;
  • Ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by histopathological examination and meeting the criteria for platinum…
  • ECOG performance status of 0 or 1；
  • Expected survival \> 12 weeks;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →